|
EP0966297B2
(en)
|
1996-08-08 |
2013-02-27 |
Amylin Pharmaceuticals, Inc. |
Regulation of gastrointestinal motility
|
|
US5783556A
(en)
*
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
|
US7312196B2
(en)
*
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
JP4647736B2
(ja)
*
|
1999-09-30 |
2011-03-09 |
小林製薬株式会社 |
薬剤発散具
|
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
|
CN101822822A
(zh)
*
|
2009-03-04 |
2010-09-08 |
北京德众万全药物技术开发有限公司 |
一种普兰林肽的药物组合物及其制备方法
|
|
JP2009149684A
(ja)
*
|
2009-03-11 |
2009-07-09 |
Amylin Pharmaceut Inc |
アミリン作動薬ペプチド用製剤
|
|
CN102145164B
(zh)
*
|
2010-12-16 |
2013-02-27 |
深圳市健元医药科技有限公司 |
一种更加稳定的iapp类似物注射剂
|
|
US9399065B2
(en)
|
2012-04-16 |
2016-07-26 |
Biodel Inc. |
Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
MX362190B
(es)
|
2012-12-21 |
2019-01-08 |
Sanofi Sa |
Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
WO2015168488A2
(en)
|
2014-05-02 |
2015-11-05 |
The Research Foundation For The State University Of New York |
Islet amyloid polypeptides with improved solubility
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
CN107952064B
(zh)
*
|
2016-10-14 |
2023-10-20 |
江苏豪森药业集团有限公司 |
含有聚乙二醇洛塞那肽的药物制剂及其制备方法
|
|
WO2018122278A1
(fr)
*
|
2016-12-27 |
2018-07-05 |
Adocia |
Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
|
US11028137B2
(en)
|
2017-02-01 |
2021-06-08 |
The Research Foundation For The State University Of New York |
Mutant islet amyloid polypeptides with improved solubility and methods for using the same
|
|
JP6633777B2
(ja)
|
2017-08-24 |
2020-01-22 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１組成物及びその使用
|
|
US11110063B2
(en)
|
2017-08-25 |
2021-09-07 |
MAIA Pharmaceuticals, Inc. |
Storage stable sincalide formulations
|
|
AU2021208601B2
(en)
*
|
2020-02-18 |
2025-06-05 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
|
US20240299552A1
(en)
*
|
2020-12-16 |
2024-09-12 |
Zealand Pharma A/S |
Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
|
|
ES3010934T3
(en)
*
|
2022-05-30 |
2025-04-04 |
Zealand Pharma As |
Liquid formulations of amylin analogues
|